by TractManager | Oct 10, 2019 | Emerging Technology Report
Scenesse is a subcutaneous implant containing a synthetic analog of alpha-melanocyte stimulating hormone. It is indicated to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria.If you have a...
by TractManager | Oct 10, 2019 | Emerging Technology Report
Scenesse is a subcutaneous implant containing a synthetic analog of alpha-melanocyte stimulating hormone. It is indicated to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria.If you have a...
by TractManager | Oct 9, 2019 | Health Technology Assessment
Health Problem: Pediatric chronic rhinosinusitis (PCRS) affects from 1.7 to 4.4 million children in the United States and is associated with an estimated annual expenditure of $1.8 billion. PCRS places a large burden of morbidity on children due to persistent...
by TractManager | Oct 8, 2019 | Emerging Technology Report
Endari (oral pharmaceutical grade L-glutamine) is an amino acid with antioxidant properties indicated to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients 5 years of age and older. It is a precursor for nicotinamide adenine...
by TractManager | Oct 8, 2019 | Emerging Technology Report
Endari (oral pharmaceutical grade L-glutamine) is an amino acid with antioxidant properties indicated to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients 5 years of age and older. It is a precursor for nicotinamide adenine...
Recent Comments